Influence of RGS2 on sertraline treatment for social anxiety disorder

Neuropsychopharmacology

Volumn 39, Issue 6, 2014, Pages 1340-1346

  Stein, Murray B ^a   Keshaviah, Aparna ^b   Haddad, Stephen A ^b   Van Ameringen, Michael ^c   Simon, Naomi M ^b   Pollack, Mark H ^d   Smoller, Jordan W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

genetics; pharmacotherapy; selective serotonin reuptake inhibitor; social anxiety disorder

Indexed keywords

BIOLOGICAL MARKER; SERTRALINE; NORADRENALIN TRANSPORTER; PHARMACOLOGICAL BIOMARKER; RGS PROTEIN; RGS2 PROTEIN, HUMAN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SLC6A2 PROTEIN, HUMAN; SLC6A4 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE; GENE CLUSTER; GENETIC VARIABILITY; HTR2A GENE; HUMAN; LIEBOWITZ SOCIAL ANXIETY SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTRANSMISSION; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RGS2 GENE; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SLC6A2 GENE; SLC6A4 GENE; SOCIAL PHOBIA; TREATMENT RESPONSE; ANXIETY DISORDERS; CLINICAL TRIAL; GENETICS; GENOTYPING TECHNIQUE; MULTIVARIATE ANALYSIS; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; ANXIETY DISORDERS; BIOMARKERS, PHARMACOLOGICAL; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MALE; MULTIVARIATE ANALYSIS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; RGS PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 84900790084     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.301     Document Type: Article

References (26)

1. Arbelle S, Benjamin J, Golin M, Kremer I, Belmaker RH, Ebstein RP (2003). Relation of shyness in grade school children to the genotype for the long form of the serotonin transporter promoter region polymorphism. Am J Psychiatry 160: 671-676. (Pubitemid 41079598)
2. Fresco DM, Coles ME, Heimberg RG, Liebowitz MR, Hami S, Stein MB et al (2001). The Liebowitz Social Anxiety Scale: a comparison of the psychometric properties of self-report and clinician-administered formats. Psychol Med 31: 1025-1035. (Pubitemid 32725348)
3. Gelernter J, Page GP, Stein MB, Woods SW (2004). Genome-wide linkage scan for loci predisposing to social phobia: evidence for a chromosome 16 risk locus. Am J Psychiatry 161: 59-66. (Pubitemid 38419308)
4. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A et al (2009). Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 195: 30-38.
5. Kimple AJ, Bosch DE, Giguere PM, Siderovski DP (2011). Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev 63: 728-749.
6. Laje G, Perlis RH, Rush AJ, McMahon FJ (2009). Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv 60: 1446-1457.
7. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV (1997). Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 27: 93-105. (Pubitemid 27407503)
8. Lifschytz T, Broner EC, Zozulinsky P, Slonimsky A, Eitan R, Greenbaum L et al (2012). Relationship between Rgs2 gene expression level and anxiety and depression-like behaviour in a mutant mouse model: serotonergic involvement. Int J Neuropsychopharmacol 15: 1307-1318.
9. Masi G, Pfanner C, Mucci M, Berloffa S, Magazu A, Parolin G et al (2012). Pediatric social anxiety disorder: predictors of response to pharmacological treatment. J Child Adolesc Psychopharmacol 22: 410-414.
10. Nyholt DR (2004). A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74: 765-769. (Pubitemid 38420107)
11. Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, Bai D, Houston FP, Whishaw IQ et al (2000). Regulation of T cell activation, anxiety, and male aggression by RGS2. Proc Natl Acad Sci USA 97: 12272-12277.
12. Perlis RH (2010). Can single genes matter in a polygenic world? Biol Psychiatry 68: 783-784.
13. Perlis RH (2011). Translating biomarkers to clinical practice. Mol Psychiatry 16: 1076-1087.
14. Pollack MH, Van Ameringen M, Simon NM, Worthington JW, Hoge EA, Keshaviah A et al (2013). A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry (in press).
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575. (Pubitemid 47330214)
16. Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC (2008). Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med 38: 15-28. (Pubitemid 350275216)
17. Semplicini A, Lenzini L, Sartori M, Papparella I, Calo LA, Pagnin E et al (2006). Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens 24: 1115-1124. (Pubitemid 43772320)
18. Smoller JW, Paulus MP, Fagerness JA, Purcell S, Yamaki LH, Hirshfeld-Becker D et al (2008). Influence of RGS2 on anxietyrelated temperament, personality, and brain function. Arch Gen Psychiatry 65: 298-308. (Pubitemid 351342446)
19. Stein DJ, Ipser JC, Balkom AJ (2004). Pharmacotherapy for social phobia. Cochrane Database Syst Rev CD001206.
20. Stein MB, Seedat S, Gelernter J (2006). Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl) 187: 68-72. (Pubitemid 43876918)
21. Stein MB, Stein DJ (2008). Social anxiety disorder. Lancet 371: 1115-1125. (Pubitemid 351418007)
22. Talbot JN, Jutkiewicz EM, Graves SM, Clemans CF, Nicol MR, Mortensen RM et al (2010). RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects. Proc Natl Acad Sci USA 107: 11086-11091.
23. Uher R, Tansey KE, Malki K, Perlis RH (2012). Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 13: 233-240.
24. Van Ameringen M, Oakman J, Mancini C, Pipe B, Chung H (2004). Predictors of response in generalized social phobia: effect of age of onset. J Clin Psychopharmacol 24: 42-48. (Pubitemid 38134165)
25. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P et al (2004). A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61: 1153-1162. (Pubitemid 39463417)
26. Yalcin B, Willis-Owen SA, Fullerton J, Meesaq A, Deacon RM, Rawlins JN et al (2004). Genetic dissection of a behavioral quantitative trait locus shows that Rgs2 modulates anxiety in mice. Nat Genet 36: 1197-1202. (Pubitemid 41288969)